Latest Operational Expansion News

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

LGI Limited reported robust half-year results for December 2025, showcasing strong revenue and profit growth alongside operational expansion and strategic debt repayment.

Austral Resources Australia Ltd has resumed trading on the ASX following news of a significant capital raising and a strategic investor commitment, signaling renewed confidence in the company’s future.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Austral Resources Australia has voluntarily suspended its shares on the ASX to complete a significant placement and secure a strategic investor commitment, with strong demand reported.

29Metals has successfully completed the retail portion of its entitlement offer, raising $31 million and finalising a $150 million capital injection to support its growth ambitions.

New Hope Corporation reported a 4.8% rise in coal production and an 8.2% increase in sales for the January quarter, maintaining steady earnings and reducing capital expenditure guidance amid improving logistics and operational resilience.

Viva Leisure Limited has reported a robust half-year performance for the period ending 31 December 2025, with revenues climbing 17.6% and profit after tax soaring by 167.8%. The company’s strategic focus on franchise expansion and technology innovation is driving growth.

HighCom Limited has announced a $7 million capital raise alongside a $1 million Share Purchase Plan to support working capital and product innovation, aiming for a strong revenue rebound and profitability in the second half of FY26.

Black Cat Syndicate has appointed James Bruce as its new Managing Director, signaling a strategic leadership transition aimed at advancing its multi-site gold production and growth ambitions.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.